YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
ResMed (RMD): Buy, Sell, or Hold Post Q2 Earnings? ResMed currently trades at $218.94 per share and has shown little upside over the past six months, posting a small loss of 2.7%. The stock also fell short of the S&P 500's 15.9% gain durin…
2 Cash-Producing Stocks with Promising Prospects and 1 We Brush Off Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, lead…
Resmed, Inc. SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2027 on Thursday, October 29, 2026, after the…
Glucose monitoring company DexCom’s investment in Oura values the company at just over $5 billion. Oura is looking to go public at a valuation above $15 billion. Continue Reading
ResMed Inc. (NYSE:RMD) is well positioned to benefit from the long-term growth of the global obstructive sleep apnea (OSA) treatment market. Likewise, the company remains well positioned to benefit from growing awareness and penetration in…
Sleep device maker ResMed rose Tuesday after the stock notched an upgrade and price target increase on Wall Street. RBC Capital analysts boosted the stock’s rating to Outperform from Sector Perform on Tuesday, while lifting the price targe…
Earlier this year, ResMed reported quarterly results showing revenue of US$1.46 billion, up 8.6% year on year, with adjusted earnings per share ahead of expectations but accompanied by operating margin pressure from higher R&D and supply c…
ResMed (RMD) is projected to attain high-single-digit EPS growth over the next three years, despite PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
Resmed RMD benefits from the portfolio reduction of its Residential Care Software segment, which is poised to continue supporting its growth in the coming quarters. The company continues to expand its mask portfolio through product innovat…
Patient Monitoring Stocks Q2 Teardown: ResMed (NYSE:RMD) Vs The Rest Wrapping up Q2 earnings, we look at the numbers and key takeaways for the patient monitoring stocks, including ResMed (NYSE:RMD) and its peers. Patient monitoring compani…
Healthcare Technology Executive to Lead MatrixCare's Next Phase of Growth and Product Innovation SEATTLE, September 01, 2026--(BUSINESS WIRE)--Frazier Healthcare Partners ("Frazier"), a private equity firm focused exclusively on the health…
2 Profitable Stocks Worth Investigating and 1 We Turn Down While profitability is essential, it doesn't guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said…
Resmed, Inc. SAN DIEGO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Aaron Bloomer, chief financial officer, will attend the 24th Annual Morgan Stanl…
2 S&P 500 Stocks with Promising Prospects and 1 We Ignore While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials,…
Reddick, a 13-time NASCAR Cup Series winner and 2026 Daytona 500 Champion, shares how prioritizing sleep health is an important part of his recovery and performance routine SAN DIEGO, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, AS…
Moderna upgraded, Baidu downgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by…
Resmed, Inc. Nominating and Governance Chair Carol Burt to become Lead Director. Ron Taylor to retire after more than 21 years of service on Resmed's Board of Directors. SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX:…
On August 6, ResMed (NYSE:RMD) reported fourth-quarter fiscal 2026 results capping a year of double-digit growth. Quarterly revenue rose 9% to $1.5 billion, and non-GAAP earnings per share jumped 16% to $2.95. For the full fiscal year, whi…
The 5 Most Interesting Analyst Questions From ResMed's Q2 Earnings Call ResMed's second quarter saw steady revenue growth, but the market responded negatively as the company's operating margin declined year over year. Management attributed…
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. ResMed stock has lagged over the past year, yet both the Discounted Cash Flow (DCF) intrinsic value estimate and the market multipl…
In early August 2026, ResMed reported past fourth-quarter and full-year results showing higher sales and earnings, announced a 10% increase in its quarterly US$0.66 dividend, and confirmed completion of a long-running US$1.40 billions shar…
Inogen, Inc. INGN lowered its 2026 revenue outlook after second-quarter results showed continued U.S. channel pressure despite better profitability and international growth. The revision puts more focus on how quickly the company can adapt…
Inogen, Inc. INGN trades at a steep sales-multiple discount even as second-quarter 2026 margins improved and international demand remained firm. The disconnect creates an interesting setup, but the operating recovery is not yet broad-based…
RMD Q2 Deep Dive: Margin Pressures Weigh Despite Product Momentum and Portfolio Shifts Medical device company ResMed (NYSE:RMD) met Wall Street's revenue expectations in Q2 CY2026, with sales up 8.6% year on year to $1.46 billion. Its non-…
Resmed Inc. RMD reported fourth-quarter fiscal 2026 adjusted earnings of $2.95 per share, which rose 16% year over year and outpaced the Zacks Consensus Estimate by 1.72%. For the full year, the adjusted EPS of $11.17 topped the Zacks Cons…
This article first appeared on GuruFocus. Revenue: Group revenue for Q4 FY2026 was $1.5 billion, a 9% headline increase and 8% growth on a constant currency basis. Non-GAAP Earnings Per Share: Increased by 16% to $2.95 in the fourth quarte…
ResMed (NYSE:RMD) Posts Q2 CY2026 Sales In Line With Estimates But Stock Drops Medical device company ResMed (NYSE:RMD) met Wall Street's revenue expectations in Q2 CY2026, with sales up 8.6% year on year to $1.46 billion. Its non-GAAP pro…
ResMed (RMD) came out with quarterly earnings of $2.95 per share, beating the Zacks Consensus Estimate of $2.9 per share. This compares to earnings of $2.55 per share a year ago. These figures are adjusted for non-recurring items. This qua…
Resmed, Inc. Q4 revenue increased by 9% to a record $1.5 billion; up 8% on a constant currency basis Q4 GAAP diluted earnings per share up 2% to $2.64; non-GAAP diluted earnings per share up 16% to $2.95 Returned $1.0 billion to shareholde…
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Why the upcoming ResMed earnings matter ResMed (RMD) is back in focus ahead of its forthcoming earnings report, with Wall Street pr…
Inspire Medical Systems, Inc. INSP offers investors a difficult trade-off. Its underpenetrated obstructive sleep apnea market, improving margins and financial flexibility support the long-term case. Near-term execution remains less certain…
Inspire Medical Systems, Inc. INSP shares have gained 28.1% in the past month, shifting attention to whether improving earnings expectations can support additional upside. The rally follows a quarterly earnings beat, higher 2026 guidance a…
As the second-quarter earnings season progresses, this week marks an important period for many medical-sector companies. Per the latest Earnings Preview report, the Medical sector's earnings might have suffered due to a dull macroeconomic…
Analysts on Wall Street project that ResMed (RMD) will announce quarterly earnings of $2.90 per share in its forthcoming report, representing an increase of 13.7% year over year. Revenues are projected to reach $1.46 billion, increasing 8.…
Viemed Healthcare, Inc. (VMD) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.08 per share a year ago. These figures are adjusted for non-recurrin…
1 Cash-Producing Stock on Our Watchlist and 2 We Find Risky Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to m…